ZLDPY (Zealand Pharma AS) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLDPY Zealand Pharma AS ZLDPY
42 GF Score
Price $8.67
GF Value $358.32
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Zealand Pharma AS Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

ZLDPY
42GF Score
Zealand Pharma AS ZLDPY
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (ZLDPY) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $8.67 is trading 97.6% below its estimated GF Value™ of $358.32. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPY:

  • Dividends Paid:
  • GF Value™: $358.32 vs. price of $8.67 (97.6% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the ZLDPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a Danish biotechnology company that discovers, designs, and develops peptide-based medicines, primarily for metabolic and gastrointestinal diseases. Its pipeline includes dasiglucagon, a glucagon analog approved as Zegalogue for severe hypoglycemia and developed for congenital hyperinsulinism and bihormonal artificial pancreas systems; glepaglutide for short bowel syndrome; and survodutide, a dual GLP-1/glucagon receptor agonist licensed to Boehringer Ingelheim for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. The company also has partnered programs with other pharmaceutical companies, generating revenue through licensing fees, milestone payments, and royalties. Zealand Pharma is headquartered in Copenhagen, Denmark, and is listed on Nasdaq Copenhagen and, through American Depositary Receipts, on Nasdaq in the United States. Its customers and collaborators are primarily large pharmaceutical companies and healthcare providers in Europe, North America, and other developed markets.
42GF Score

Get the complete analysis for ZLDPY

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.67
Price
$358.32
GF Value